StockWatch
·
PHARMA · MOREPEN LABORATORIES · BSE 500288

Morepen launches its first US prescription generic, moving from API supplier toward finished-dose sales

Desloratadine 5 mg goes on sale in the U.S. via Morepen Bio Inc; a first ANDA, for Sitagliptin, is under FDA review. It lands on Q2 FY27 revenue of ₹746.5 Cr, up 81% YoY.

MOREPENLABMorepen Laboratories Ltd09 Nov 2026 · 4 min read
Size tier

MID-CAP

by market cap ≈ ₹7,004.5 Cr

Last close in pack

₹127.83

Oct 12 — most recent price in this report's data

52-week range

₹33.05–₹150.70

low Mar 30 · high Oct 7 (adjusted)

Q2 FY27 revenue

₹746.5 Cr

consolidated, +81.4% YoY

Q2 FY27 net profit

₹88.9 Cr

OPM 16.5% · EPS ₹1.62

Promoter holding

35.65%

unchanged Mar → Jun 2026

Before Monday's open, Morepen Laboratories filed a press release announcing the launch of its first prescription (Rx) generic product — Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs — for distribution in the U.S. market, through its wholly owned U.S. arm, Morepen Bio Inc. The company says it has supplied Desloratadine API to the U.S. for many years; this launch extends its participation along the value chain into finished-dosage medicines and U.S. distribution, following earlier U.S. OTC product introductions.

What the filing says

From selling the ingredient to selling the tablet

pharma

Morepen enters the U.S. prescription generics market with Desloratadine Tablets USP 5 mg

Filed pre-open at 08:54 IST: Morepen launched Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs, for U.S. distribution through wholly owned Morepen Bio Inc — the company's first prescription generic. The release notes Morepen has supplied Desloratadine API to the U.S. market for many years, and that the Rx expansion follows its earlier U.S. OTC introductions. Separately, it states the company has submitted its first ANDA to the U.S. FDA — Sitagliptin Phosphate Tablets USP, 25 mg, 50 mg and 100 mg — currently under regulatory review.

Read:A finished-dose sale in the U.S. is a different business from supplying the API for someone else's tablet — the filing frames it as extending participation along the pharmaceutical value chain. The release gives no revenue figures or volume guidance for the launch, so the financial size of this step is not yet measurable from company disclosures.

BSE filing — press release, Nov 9, 2026

The forward intent is stated explicitly: Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities where its API and pharmaceutical R&D capabilities provide an advantage, and may also evaluate selected opportunities in high-potency APIs (HPAPIs) and oncology — the latter expressly subject to development feasibility, regulatory requirements and market conditions. Those are stated intentions, not commitments with dates attached.

Management framing
Our long-standing API relationships in regulated markets provide a strong foundation for Morepen's next phase of growth. Alongside our expanding CDMO business, we are selectively extending our capabilities into finished-dosage development and U.S. distribution. This reflects our strategy to build a more integrated, R&D-led pharmaceutical business with sustainable, long-term growth opportunities.

— Sanjay Suri, Managing Director — company press release, Nov 9, 2026

The launch is the second leg of a sequence that began six weeks earlier. On September 28, Morepen announced its first ANDA submission — Sitagliptin Tablets USP in three strengths — framed as strengthening formulation, bioequivalence and regulatory-dossier capabilities. The Desloratadine launch itself does not depend on that ANDA: it is already on sale, while the Sitagliptin application sits with the FDA.

+0.3% (Sep 28, session of the filing)
pharma

First U.S. ANDA submitted — Sitagliptin Tablets USP in three strengths

A pre-open press release (08:53 IST) announced Morepen's first Abbreviated New Drug Application to the U.S. FDA, for Sitagliptin Tablets USP, described as advancing the company's API-to-finished-dosage development offering and supporting its CDMO capabilities.

Read:The market barely moved on the day — the stock closed at ₹120.71 against ₹120.38 the prior session. The November 9 launch filing confirms the application remains under regulatory review.

BSE filing — press release, Sep 28, 2026
The quarter behind it

The launch lands on a record quarter

₹ Cr, consolidated quarterly revenue
0278.69557.39836.08411.58Q2 FY26PAT 40.9484.16Q3 FY26PAT 27.5484.72Q4 FY26PAT 15.7570.13Q1 FY27PAT 56.4746.5Q2 FY27PAT 88.9
Consolidated quarterly revenue, Q2 FY26–Q2 FY27, ₹ crore. Source: exchange filings.

Q2 FY27, reported on October 27, was the context this launch arrives into: consolidated revenue of ₹746.5 crore, up 81.4% over the ₹411.6 crore of Q2 FY26, with net profit of ₹88.9 crore against ₹40.9 crore a year earlier — and the year-ago quarter had included an exceptional gain of ₹25.8 crore. Operating margin reached 16.5%, versus 5.0% two quarters prior. The company's own press release headlined it as a record Q2 — revenue of ₹755 crore (the total-income figure), EBITDA up 273% to ₹132 crore, and H1 EBITDA of ₹220 crore — crediting CDMO momentum. The U.S. generics launch adds a new revenue line on top of that base; how large a line, no disclosure yet says.

Consolidated quarterly P&L · ₹ Cr
QuarterRevenueNet profitOPMEPS (₹)
Q2 FY27746.588.8916.49%1.62
Q1 FY27570.1356.414.48%1.03
Q4 FY26484.7215.745.04%0.28
Q3 FY26484.1627.519.57%0.5
Q2 FY26411.5840.8713.73%0.75

Q2 FY26 net profit includes an exceptional item of ₹25.83 Cr. Source: exchange filings.

The tape

A near-four-fold year, then a pull-back the series doesn't yet show

₹, daily close (adjusted)
41.1170.4199.71129.01158.31127.8307-1708-0708-2809-2110-12First U.S. ANDA press release52-week high ₹150.70 touched
Morepen Laboratories (BSE 500288), split/bonus-adjusted daily closes, Jul 17–Oct 12, 2026 — the most recent sessions available in this report's price data. Source: BSE.

The stock's year has been extraordinary on the adjusted series: a 52-week low of ₹33.05 on March 30, a 52-week high of ₹150.70 on October 7, and a close of ₹127.83 on October 12 — up roughly 287% from the low and 15.2% below the high. The series in this report ends there, but a November 4 bulk deal fills in part of the gap: Neo Apex Share Broking Services LLP bought 36.68 lakh shares at ₹97.20 (about ₹35.6 crore) and sold 3,200 shares at ₹106.99 the same day — a net purchase of roughly 36.6 lakh shares. The ₹97.20 deal price indicates the stock had pulled back well below its October levels by early November. Two cautions on reading that deal: the buyer is a share-broking LLP, so the record does not establish institutional buying, and the deal predates the launch announcement by five days — it cannot have been a reaction to it.

  1. Pre-open press release: first U.S. ANDA submitted — Sitagliptin Tablets USP in three strengths.

  2. Himachal Pradesh High Court judgment (dated Oct 12) quashed the GST show-cause notice seeking recovery of ₹117,94,03,452 — i.e. ₹117.9 crore — disposing of the writ petition in the company's favour.

  3. Q2 & H1 FY27 results approved; company press release headlines record Q2 revenue of ₹755 Cr and EBITDA of ₹132 Cr. Care Ratings' monitoring-agency report on the ₹200 Cr QIP proceeds filed the same day.

  4. Nishant Jayesh Doshi, Vice President — Corporate Finance & Investor Relations, resigned effective the same day to pursue a new professional opportunity.

  5. Bulk deal: Neo Apex Share Broking Services LLP bought 36,67,667 shares at ₹97.20 and sold 3,200 at ₹106.99.

  6. Pre-open press release: first U.S. prescription generic — Desloratadine Tablets USP 5 mg — launched through Morepen Bio Inc.

What to watch

The filings that would change this picture

  • Sitagliptin ANDA

    The application is under FDA review per the Nov 9 release. An approval would give Morepen its second U.S. prescription product — and the first it took through the full ANDA route itself.

  • Desloratadine in the numbers

    Q3 FY27 results (quarter ending December 2026) are the first place U.S. finished-dose revenue could become visible. Today's release gives no revenue or volume figures for the launch.

  • Further Rx filings

    The company states it intends additional U.S. prescription generic filings, and may evaluate HPAPIs and oncology — conditional language worth tracking against actual submissions.

  • QIP utilisation

    Care Ratings files quarterly monitoring reports on the ₹200 Cr QIP proceeds; the next one will show how the capital is being deployed.

The November 9 filing marks a stated change in what Morepen sells in the U.S.: for years the company supplied Desloratadine as an ingredient; it now also sells the finished tablet there, through its own subsidiary. The filing frames this as extending participation along the pharmaceutical value chain, alongside the CDMO business the company credits for its record Q2. What no disclosure yet provides is scale — the launch carries no revenue, volume or market-share figures.

The data suggests the operating base this lands on is the strongest in the period covered here: revenue up 81.4% year-on-year, operating margin at 16.5%, and a GST contingency of ₹317.37 crore (inclusive of recovery, interest and penalty) removed by a High Court order in October. Against that, the price information is incomplete — the adjusted series ends October 12 at ₹127.83, while a November 4 bulk deal at ₹97.20 indicates a meaningful pull-back since. Key monitorables are the Sitagliptin ANDA outcome and whether U.S. finished-dose sales appear in the Q3 FY27 disclosures.

Informational and educational content only. Not investment advice.